Skip to main content
Top
Published in: Diabetologia 10/2009

01-10-2009 | Letter

Diabetic retinopathy and insulin glargine

Author: E. Chantelau

Published in: Diabetologia | Issue 10/2009

Login to get access

Excerpt

To the Editor: The recent paper by Rosenstock et al. [1] published in Diabetologia claims that ‘this study was specifically designed to detect differences in the incidence of retinopathy progression by fundus photography over a 5 year period’ and that it demonstrated ‘similar progression of diabetic retinopathy with insulin glargine (A21Gly,B31Arg,B32Arg human insulin) and neutral protamine Hagedorn (NPH) insulin’. The authors explain that, to verify progression status, a side-by-side comparison of baseline and follow-up photographs was conducted for any patient whose Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy severity scale score progressed by three steps or more, compared with baseline, at any time point during the study. However, Table 1 shows that only 80 out of 513 patients on insulin glargine, and 61 out of 504 patients on NPH, had any diabetic retinopathy at baseline. Among those without retinopathy at baseline, retinopathy can develop but it cannot progress; incidence rates of newly developing retinopathy and progression rates of pre-existing retinopathy must not be confused. In the DCCT study, for instance, the proportion of participants whose retinopathy had progressed by three or more steps at 5 years was approx. 15–35% (secondary intervention group), which was clearly different from the 5 year incidence of retinopathy (change in ETDRS score of at least three steps from baseline) of approximately 5–15% in cases without retinopathy at baseline (primary prevention group) [2]. The estimate for power calculations by Rosenstock et al. [1], a 20% 5 year event rate, was taken from the DCCT data [1]. However, the DCCT only included type 1 diabetic patients. In the UK Prospective Diabetes Study on type 2 diabetic patients, cases without pre-existing retinopathy progressed much slower than those with; indeed, the 6 year event rate was less than half that in the DCCT [3]. Hence, the study by Rosenstock and colleagues [1] was considerably underpowered. …
Literature
1.
go back to reference Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.1007/s00125-009-1415-7 Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.​1007/​s00125-009-1415-7
2.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
go back to reference Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (UKPDS) Group (2001) Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabetic Med 18:178–184PubMedCrossRef Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (UKPDS) Group (2001) Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabetic Med 18:178–184PubMedCrossRef
Metadata
Title
Diabetic retinopathy and insulin glargine
Author
E. Chantelau
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1488-3

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine